UCP2 and neoplasm: Knockdown of UCP2 in NSCLC cell lines reduced the tumor inhibition rates of chemotherapeutic agents, whereas overexpression of UCP2 sensitized refractory cell lines to chemotherapy (Figure 2F to 2H).